Filing Details
- Accession Number:
- 0001209191-20-054321
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-10-08 18:27:13
- Reporting Period:
- 2020-10-06
- Accepted Time:
- 2020-10-08 18:27:13
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1671818 | Oncorus Inc. | ONCR | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1134657 | Luke Evnin | C/O Oncorus, Inc. 50 Hampshire Street, Suite 401 Cambridge MA 02139 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-10-06 | 1,525,346 | $0.00 | 1,641,169 | No | 4 | C | Indirect | See footnote |
Common Stock | Acquisiton | 2020-10-06 | 700,449 | $0.00 | 2,341,618 | No | 4 | C | Indirect | See footnote |
Common Stock | Acquisiton | 2020-10-06 | 151,225 | $15.00 | 2,492,843 | No | 4 | P | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See footnote |
No | 4 | C | Indirect | See footnote |
No | 4 | P | Indirect | See footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series A-1 Preferred Stock | Disposition | 2020-10-06 | 1,525,346 | $0.00 | 1,525,346 | $0.00 |
Common Stock | Series B Preferred Stock | Disposition | 2020-10-06 | 700,449 | $0.00 | 700,449 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.
- The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
- The shares are held as follows: 1,382,943 by MPM BioVentures 2014, L.P. ("BV 2014"), 92,239 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 50,164 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 115,823 by MPM Asset Management LLC ("AM LLC"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. The Reporting Person is a member of BV LLC and AM LLC.
- The shares are held as follows: 2,018,001 by BV 2014, 134,595 by BV 2014(B), 73,199 by AM BV2014 and 115,823 by AM LLC.
- The shares are held as follows: 2,155,108 by BV 2014, 143,740 by BV 2014(B), 78,172 and 115,823 by AM LLC.
- The shares are held as follows: 1,382,943 by BV 2014, 92,239 by BV 2014(B) and 50,164 by AM BV2014.
- The shares are held as follows: 635,058 by BV 2014, 42,356 by BV 2014(B) and 23,035 by AM BV2014.